RA Capital Management 13F holdings, Q1 2017
Holdings as of March 31, 2017 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 24 US equity positions worth $815.3m in its Q1 2017 13F filing. The largest position was WVE at 23.9% of the reported book, followed by ASND and AVEXIS INC. Against the Q4 2016 filing, it opened 5 new positions, added to 2 and reduced 4 among the top 24 holdings.
What did RA Capital Management own in Q1 2017? Top 24 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2016 |
|---|---|---|---|---|---|---|---|
| 1 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 23.9% | $194.9m | 7,088,651 | 0% | held |
| 2 | ASND ASCENDIS PHARMA A S | Healthcare | 18.6% | $151.5m | 5,409,990 | 0% | held |
| 3 | AVEXIS INC | 15.2% | $123.6m | 1,625,211 | -14% | reduced | |
| 4 | ACHILLION PHARMACEUTICALS INC | 7.0% | $57.4m | 13,633,220 | 0% | held | |
| 5 | AQUINOX PHARMACEUTICALS INC | 4.4% | $36.2m | 2,184,047 | -0% | held | |
| 6 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 3.6% | $29.3m | 3,489,795 | 17% | added |
| 7 | RA PHARMACEUTICALS INC | 3.5% | $28.8m | 1,351,808 | 0% | held | |
| 8 | MYOVANT SCIENCES LTD | 3.4% | $27.6m | 2,348,422 | 57% | added | |
| 9 | ZOGENIX INC | 3.3% | $26.6m | 2,451,237 | 0% | held | |
| 10 | ESPERION THERAPEUTICS INC | 3.1% | $24.9m | 704,701 | – | new | |
| 11 | LOXO ONCOLOGY INC | 1.5% | $12.6m | 298,935 | – | new | |
| 12 | ARDX ARDELYX INC | Healthcare | 1.3% | $10.5m | 828,283 | -57% | reduced |
| 13 | ACORDA THERAPEUTICS INC | 1.3% | $10.3m | 489,828 | – | new | |
| 14 | AUDENTES THERAPEUTICS INC | 1.1% | $9.1m | 532,426 | 0% | held | |
| 15 | FOAMIX PHARMACEUTICALS LTD | 1.1% | $9.0m | 1,820,138 | 0% | held | |
| 16 | IGNYTA INC | 1.1% | $8.8m | 1,025,291 | – | new | |
| 17 | ONC BEIGENE LTD | Healthcare | 1.1% | $8.8m | 240,000 | 0% | held |
| 18 | CALITHERA BIOSCIENCES INC | 1.0% | $8.4m | 725,000 | – | new | |
| 19 | DICERNA PHARMACEUTICALS INC | 1.0% | $8.3m | 2,428,571 | 0% | held | |
| 20 | TGTX TG THERAPEUTICS INC | Healthcare | 1.0% | $8.2m | 700,000 | -30% | reduced |
| 21 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 1.0% | $8.2m | 636,248 | -8% | reduced |
| 22 | 4XC1 KALVISTA PHARMACEUTICALS INC | 0.6% | $4.6m | 591,070 | 0% | held | |
| 23 | EIGER BIOPHARMACEUTICALS INC | 0.5% | $4.1m | 354,200 | 0% | held | |
| 24 | MEDICINES CO | 0.5% | $3.9m | 79,899 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.